Larimar Therapeutics, Inc. (LRMR) Earnings
Larimar Therapeutics, Inc. is expected to report next earnings on August 13, 2026 (in NaN days), with a consensus EPS estimate of $-0.39. LRMR has beaten EPS estimates in 6 of its last 12 reported quarters (average surprise -17.0% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 14, 2026 | $-0.53 | $-0.31 | +41.5% | — | — |
| Mar 19, 2026 | $-0.44 | $-0.73 | -65.9% | — | — |
| Nov 5, 2025 | $-0.39 | $-0.61 | -56.4% | — | — |
| Aug 14, 2025 | $-0.47 | $-0.41 | +12.8% | — | — |
| Apr 30, 2025 | $-0.42 | $-0.46 | -9.5% | — | — |
| Mar 24, 2025 | $-0.29 | $-0.45 | -55.2% | $241000 | — |
| Oct 30, 2024 | $-0.37 | $-0.24 | +35.1% | — | — |
| May 9, 2024 | $-0.24 | $-0.27 | -12.5% | — | — |
| Mar 14, 2024 | $-0.25 | $-0.30 | -20.0% | — | — |
| Nov 14, 2023 | $-0.23 | $-0.21 | +8.7% | — | — |
| Aug 10, 2023 | $-0.21 | $-0.19 | +9.5% | — | — |
| May 15, 2023 | $-0.25 | $-0.15 | +40.0% | — | — |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q1 FY2023 · September 29, 2025
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
- Positive 25-milligram and 50-milligram data from the long-term open-label study for Friedreich's ataxia patients, showing increased tissue frataxin and clinical outcome improvements. - Safety: 7 participants had anaphylaxis, most on initial administration day; dosing regimen modified with 5-milligram test dose, antihistamines, and EpiPen for participants. - Development program: Amending open-label study protocol to include adolescents and adults not in prior studies; global Phase III study in progress, qualifying sites globally. - Clinical outcomes: Compared to FACOMS reference population, observed 2.25 point improvement in mFARS over 1 year vs. 1 point worsening in reference, and improvements in other measures.
Guidance
- Targeting BLA submission in the second quarter of 2026, seeking accelerated approval. - Confident in nomlabofusp's potential as a disease-modifying therapy for Friedreich's ataxia.
Segment performance
The company's lead program is nomlabofusp for Friedreich's ataxia. Positive data from a long-term open-label study showed consistent directional improvements in key clinical outcome measures like mFARS, FARS ADL, 9-hole PEG test, and MFIS. Skin frataxin levels increased, with 100% of participants at 6 months achieving over 50% of healthy volunteer levels. No traditional product segment revenue contribution discussed as it's a clinical stage biotech focused on one program.
Risks & headwinds
- Anaphylaxis events in 7 participants, with most occurring on initial administration; risk of allergic reactions and need to consider in context of the disease. - Uncertainties in clinical trial data interpretation, success, cost, and timing of product development activities; ability to raise capital.
Analyst Q&A
Q: How does the data at 14 patients 6 months compare to historical control?
A: Can't compare at 6 months as FACOMS data is annual; best comparison at 1 year.
Q: Color on severity of anaphylaxis?
A: Treatment is standard of care (epinephrine, antihistamines, steroids), patients respond quickly.
Q: Confidence in titration dosing strategy?
A: Confident, with test dose and expert consultants; data shows patients still willing to enroll despite events.
Q: Details on 7 anaphylaxis events?
A: Most in previously dosed patients, not age-related; FDA agreed with new dosing regimen.
Q: Benefit of prophylactic antihistamines?
A: Test dose may help tie up receptors on mast cells.
Q: Rate and severity of anaphylaxis vs other ERTs?
A: Benign safety profile except anaphylaxis; differences in baseline characteristics of those who had vs didn't have anaphylaxis.
Q: Patient number data and anaphylaxis with urticaria?
A: Patient numbers related to those who received at least 1 dose; 3 urticaria cases discontinued early.
Q: mFARS data and baseline values?
A: Baselines similar to reference population; updates to be provided closer to BLA submission.
Q: Impact on confirmatory study powering?
A: Ambulatory patients have more change potential, but conservative approach to powering in Phase III.